Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Relmada Therapeutics (NASDAQ:RLMD) issued its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.09, FiscalAI reports.

Here are the key takeaways from Relmada Therapeutics’ conference call:

• NDV-01 remains on track for registrational development: Relmada plans to file the IND by year-end 2026 and begin the Phase III rescue program after clearance, with approximately 80 clinical sites prepared and 60 designated as primary sites.
• Phase II results support NDV-01’s potential: The company reported a 95% complete response rate at any time and a 76% durable complete response rate at 12 months, with favorable safety and tolerability.
• Manufacturing is the key near-term execution risk. Formulation, process development, and analytical work are complete, but Relmada still needs to secure GMP manufacturing capacity, produce batches, and generate sufficient stability data before filing the IND.
• Relmada reported substantial financial runway: Cash, cash equivalents, and short-term investments totaled $217.7 million at quarter-end, which management expects to fund operations through 2029, including completion of the NDV-01 Phase III rescue program.
• The company has not yet finalized the timing or format of additional clinical disclosures; management suggested that six-month data and a larger patient sample may be more meaningful than the previously anticipated three-month results, potentially shifting disclosure into the first half of 2027.

Relmada Therapeutics Stock Down 8.0%

Shares of RLMD traded down $0.43 during mid-day trading on Friday, hitting $4.94. 2,125,013 shares of the company’s stock traded hands, compared to its average volume of 1,542,462. The firm has a market capitalization of $518.16 million, a P/E ratio of -5.49 and a beta of 0.46. The business’s 50-day moving average price is $6.05 and its 200-day moving average price is $5.93. Relmada Therapeutics has a 1 year low of $0.55 and a 1 year high of $8.00.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Relmada Therapeutics in a research report on Thursday, June 18th. HC Wainwright started coverage on shares of Relmada Therapeutics in a research note on Thursday, June 18th. They set a “buy” rating and a $12.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Institutional Trading of Relmada Therapeutics

Large investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC purchased a new position in shares of Relmada Therapeutics during the fourth quarter valued at about $149,000. Mangrove Partners IM LLC purchased a new stake in Relmada Therapeutics in the fourth quarter worth about $132,000. Graham Capital Management L.P. bought a new stake in Relmada Therapeutics during the 4th quarter valued at approximately $124,000. Hudson Bay Capital Management LP bought a new stake in Relmada Therapeutics during the 4th quarter valued at approximately $127,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Relmada Therapeutics during the 4th quarter worth approximately $256,000. Institutional investors own 45.24% of the company’s stock.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.